Magnesium Toxicity

Etiology

Magnesium toxicity generally results from 2 primary mechanisms: excessive exogenous magnesium exposure or impaired renal clearance due to reduced kidney function. Magnesium toxicity in the acute care setting is most commonly iatrogenic. The classic clinical scenario involves obstetric patients receiving high-dose intravenous magnesium sulfate for seizure prophylaxis in severe preeclampsia or eclampsia. Standard infusion protocols can produce toxicity rapidly when concurrent preeclampsia-associated or established kidney injury goes unrecognized.[2]

Excessive, often unmonitored ingestion of over-the-counter magnesium-containing antacids, cathartics, and laxatives is the primary cause of toxicity outside intravenous administration. Risk is particularly high among older adults, in whom chronic use of these products often coincides with age-related declines in glomerular filtration rate or known chronic kidney disease. Interestingly, a large retrospective cohort study found that, although advancing age is generally associated with declining renal function, age itself did not confer an independent risk of magnesium toxicity after adjustment for renal function.[3] Less commonly, extensive cellular destruction, such as that occurring in tumor lysis syndrome, severe burns, or rhabdomyolysis, rapidly releases large amounts of intracellular magnesium into the extracellular space, precipitating acute hypermagnesemia even in the absence of exogenous magnesium exposure.

Epidemiology

Individuals at greatest risk for hypermagnesemia include patients with renal dysfunction, pregnant women receiving magnesium therapy for preeclampsia, older adults, and individuals with therapeutic misadventure or intentional overdose involving magnesium-containing supplements or medications. A population-based study reported an overall hypermagnesemia prevalence of 3.0%.

Prevalence ranges from 5.7% to 9.3% in hospital settings, increasing to an estimated 10% to 15% among admitted patients with renal failure.[4] A recent retrospective analysis demonstrated that more than 60% of patients with severe preeclampsia developed hypermagnesemia within 8 hours of initiating a standard magnesium regimen, with lower gestational age, elevated baseline uric acid, and higher baseline serum magnesium identified as independent risk factors for toxicity.[5] Clinically, an integrative review encompassing more than 9,500 women reported an overall incidence of early clinical toxicity, defined by absent patellar reflexes, of 1.6%. The overall incidence of severe toxicity, defined as magnesium-induced respiratory depression, was 1.3%.[6]

A study evaluating patients receiving magnesium supplementation for functional constipation found that approximately 5% of the 193 patients with monitored serum magnesium concentrations had hypermagnesemia, defined as a serum magnesium level greater than 3.0 mg/dL. Age alone did not correlate with elevated serum magnesium concentrations. Stage 4 chronic kidney disease and magnesium oxide doses exceeding 1,000 mg were the primary risk factors for hypermagnesemia. The clinical significance of this degree of hypermagnesemia was not evaluated.

Despite numerous studies examining the prevalence of hypermagnesemia in the general and hospitalized populations, data on the true incidence of clinically significant magnesium toxicity are limited. A study evaluating 6,252 patients found hypermagnesemia, defined as a serum magnesium level greater than 3.9 mg/dL, in 51 patients (0.8%). Only 20% of affected patients had symptoms attributed to hypermagnesemia.[7]

Pathophysiology

Magnesium toxicity primarily results from the physiologic effects of magnesium as a calcium and potassium antagonist and an N-methyl-D-aspartate (NMDA) receptor blocker. Magnesium and calcium share the same valence and similar chemical properties. Elevated extracellular magnesium competes with calcium for binding sites on multiple voltage-dependent channels. Magnesium toxicity produces diverse pathophysiologic effects because these channels and receptors are widely distributed throughout the body. The following sections summarize the mechanisms underlying the major clinical manifestations of magnesium toxicity.[8]

Vasodilation and Smooth Muscle Relaxation

Magnesium induces systemic vasodilation by directly competing with calcium at voltage-gated calcium channels in vascular smooth muscle. Competition inhibits the intracellular calcium influx required for calmodulin-dependent myosin light chain kinase activation and subsequent smooth muscle contraction. Magnesium also stimulates the endothelial release of the potent vasodilator prostaglandin I2 (prostacyclin), producing the characteristic clinical manifestations of flushing and hypotension.[9]

Neuromuscular Junction Blockade

Diminished deep tendon reflexes and muscle weakness result from neuromuscular junction blockade. Elevated magnesium acts as a physiologic calcium channel blocker at the presynaptic motor nerve terminal, preventing the calcium influx required for acetylcholine release into the synaptic cleft.[10]

Central Nervous System Depression

Magnesium normally functions as a voltage-dependent "plug" within the ion channel of the N-methyl-D-aspartate receptor, a major excitatory glutamate receptor. Hypermagnesemia enhances this noncompetitive blockade, reducing excitatory neurotransmission and producing somnolence and lethargy.[11]

Cardiac Pathophysiology

The cardiac manifestations of magnesium toxicity result from physiologic antagonism of calcium channels, stabilization of sodium channels, and interference with sodium-potassium adenosine triphosphatase (Na/K ATPase) throughout the myocardium and cardiac conduction system. As a divalent cation, extracellular magnesium competes with calcium, producing dose-dependent alterations in the cardiac action potential.[12]

Elevated magnesium levels depress conduction through the sinoatrial and atrioventricular nodes by competitively blocking T- and L-type voltage-gated calcium channels. Pacemaker cells within both nodes depend on calcium influx during phase 0 depolarization. Calcium channel blockade reduces the slope of spontaneous diastolic depolarization and slows conduction through the atrioventricular node, producing sinus bradycardia and progressive PR interval prolongation.

Magnesium toxicity also alters ventricular depolarization and repolarization. Antagonism of calcium entry through L-type calcium channels shortens the phase 2 plateau of the ventricular action potential. Magnesium also stabilizes the cardiac sodium channels responsible for phase 0 depolarization through a mechanism known as surface charge screening. Sodium channel stabilization slows intraventricular conduction and produces QRS complex widening on electrocardiography (ECG). The apparent prolongation of the QT and corrected QT intervals in magnesium toxicity is largely attributable to QRS complex widening rather than delayed ventricular repolarization.[13]

At severely toxic concentrations, extracellular magnesium directly inhibits myocardial Na/K ATPase, as demonstrated in an animal model. Na/K ATPase inhibition impairs physiologic intracellular potassium transport, creating a localized extracellular potassium gradient. The resulting membrane destabilization produces repolarization abnormalities, most notably tall, peaked T waves and prominent ST-segment elevation that may mimic ST-elevation myocardial infarction or hyperkalemia.[14]

Continued elevation of serum magnesium concentrations produces complete blockade of L-type calcium channels and profound depression of cardiac conduction. Progressive conduction abnormalities culminate in high-degree atrioventricular block, a sine wave pattern, and, ultimately, cardiac arrest.

Toxicokinetics

Magnesium is an endogenous electrolyte with toxicokinetics that closely resemble its pharmacokinetics. Clinical toxicity develops only when the rate of magnesium administration or ingestion exceeds renal elimination capacity.

Absorption

Following oral ingestion, magnesium absorption begins within approximately 1 hour, reaches a plateau after 2 to 4 hours, and is approximately 80% complete by 6 hours. Approximately 80% to 90% of magnesium absorption occurs in the jejunum and ileum of the small intestine. Small intestinal absorption occurs predominantly through paracellular transport driven by concentration gradients established by dietary magnesium intake. Several cation transporters also contribute to magnesium absorption, most notably the transient receptor potential melastatin (TRPM) channels, TRPM6 and TRPM7. These transporters are located primarily in the large intestine, where active transcellular transport independent of the intraluminal concentration gradient regulates magnesium absorption according to total body magnesium status. Overall, 24% to 76% of dietary magnesium is absorbed, with the remainder eliminated in the feces.

Distribution

Approximately 99% of total body magnesium is distributed intracellularly after absorption, with about 53% stored in bone, 27% in muscle, and 19% in nonmuscular soft tissues. The remaining 1% resides in the extracellular compartment, primarily within serum and red blood cells. Consequently, serum magnesium concentrations reflect only a small fraction of total body magnesium stores. An estimated 60% of magnesium exists in the biologically active free ionized form within the extracellular compartment, whereas the remaining 40% is bound to plasma proteins or complexed with serum anions.[15]

Metabolism

Metabolites arise from biotransformation, which involves the enzymatic alteration of chemical structure. Magnesium is an inorganic cation and does not undergo this process.

Excretion

Magnesium homeostasis is regulated primarily by the kidneys. In hypomagnesemia, fractional magnesium excretion may decrease to 0.5%, resulting in near-complete renal conservation. In contrast, normal renal function allows excretion of nearly 100% of the filtered magnesium load in the setting of magnesium excess. Only the unbound fraction of serum magnesium undergoes glomerular ultrafiltration. The proximal convoluted tubule reabsorbs a small proportion of filtered magnesium. The thick ascending limb of the loop of Henle serves as the primary site of magnesium reabsorption, predominantly through paracellular transport driven by the transepithelial voltage gradient generated by the sodium-potassium-chloride cotransporter (NKCC2) and renal outer medullary potassium (ROMK) channels. The distal convoluted tubule contains TRPM6 channels that regulate magnesium reabsorption according to systemic magnesium status. Dependence on renal function makes acute kidney injury and chronic kidney disease major risk factors for magnesium toxicity.[16][17]

History and Physical

A thorough history is essential when evaluating suspected magnesium toxicity because serum magnesium concentrations are not routinely measured, and clinical manifestations are often nonspecific. As previously discussed, magnesium toxicity results from impaired renal excretion, excessive magnesium intake, or extracellular magnesium shifts, such as those associated with tumor lysis syndrome. History-taking should focus on identifying these underlying etiologies by assessing for chronic kidney disease, use of magnesium-containing medications like antacids and laxatives, recent chemotherapy, and missed dialysis treatments.

Physical examination findings may also be nonspecific and may include visual disturbances, flushing, muscle weakness or paralysis, and somnolence. Loss of patellar reflexes should raise immediate suspicion for magnesium toxicity. Patients receiving continuous magnesium infusions, particularly for preeclampsia, require serial assessment of deep tendon reflexes.

The classic description of magnesium toxicity emphasizes a stepwise progression of clinical manifestations that generally correlates with increasing serum magnesium concentrations. Reported symptom thresholds vary across the literature. Clinical manifestations typically begin with flushing and nausea, progress to areflexia, and, ultimately, culminate in respiratory depression and asystole. Although this framework oversimplifies the clinical course, and substantial interpatient variability exists, the table below provides a practical guide to the expected signs and symptoms associated with increasing serum magnesium concentrations.[18]

Table. Clinical Manifestations of Magnesium Toxicity by Serum Magnesium Concentration

Evaluation

The evaluation of suspected hypermagnesemia begins with a thorough history. Key historical features include ingestion of magnesium-containing supplements or medications, recent chemotherapy, acute kidney injury or chronic kidney disease, and missed dialysis treatments in patients with dialysis-dependent kidney failure.

Hypermagnesemia is readily diagnosed by measuring the serum magnesium concentration. Although reference intervals vary among laboratories, normal serum magnesium levels typically range from 1.7 to 2.2 mg/dL (0.7 to 0.9 mmol/L; 1.4 to 1.8 mEq/L), with hypermagnesemia broadly defined as a concentration greater than 2.7 mg/dL (1.1 mmol/L; 2.2 mEq/L).[19] A basic or comprehensive metabolic panel should also be obtained to assess renal function and identify concurrent electrolyte abnormalities.

The evaluation of patients with suspected intentional overdose should include serum salicylate, acetaminophen, and alcohol concentrations. Additional studies, including complete blood count, lactate, troponin, blood gas analysis, creatine kinase, and urinalysis, should be guided by the clinical presentation and suspicion for concomitant disease or alternative diagnoses. Advanced imaging, such as computed tomography of the brain, may be indicated based on the clinical presentation.

Laboratory testing confirms hypermagnesemia, but overt clinical toxicity generally does not develop until serum magnesium concentrations reach 4.0 to 5.0 mg/dL (1.65 to 2.1 mmol/L; 3.3 to 4.1 mEq/L). The diagnosis of magnesium toxicity depends primarily on the clinical presentation because substantial interpatient threshold variability exists. Physical examination should include assessment of visual acuity, extraocular movements, and, most importantly, deep tendon reflexes. Given the potential for severe cardiovascular toxicity, a 12-lead ECG should also be obtained to evaluate for bradycardia, conduction abnormalities, and atrioventricular block.

Treatment / Management

Management of magnesium toxicity begins with immediate discontinuation of all magnesium administration and measures to support renal magnesium clearance. Supportive care and discontinuation of magnesium exposure are usually sufficient to reverse toxicity in patients with mild symptoms, such as flushing, modest hypotension, or hyporeflexia, and preserved renal function (glomerular filtration rate > 60 mL/min). Treatment should be guided primarily by the severity of the presenting symptoms since clinical manifestations correlate imperfectly with serum magnesium concentrations.

For severe, life-threatening manifestations, such as ECG abnormalities, profound hypotension, or respiratory depression, intravenous calcium provides immediate but temporary antagonism of magnesium-induced cardiotoxicity and neuromuscular blockade. The recommended dose is 1 to 3 g of calcium gluconate administered over 2 to 5 minutes. Repeat dosing may be necessary if severe manifestations persist. Alternatively, 0.5 to 1 g of calcium chloride may be administered by slow intravenous injection. Calcium chloride requires central venous access or a reliable large-bore peripheral intravenous catheter because extravasation carries a high risk of severe tissue necrosis.

Aggressive isotonic crystalloid administration enhances magnesium elimination by expanding intravascular volume and increasing glomerular filtration. Following adequate volume resuscitation, intravenous furosemide may be administered to inhibit magnesium reabsorption in the thick ascending limb of the loop of Henle. Hemodialysis rapidly removes magnesium from the circulation and is the definitive treatment for refractory toxicity, massive overdose, or acute kidney injury.

Differential Diagnosis

Magnesium toxicity produces systemic manifestations that overlap with several life-threatening toxicologic and neurologic emergencies because of its central nervous system depressant effects and physiologic calcium channel blockade. Severe hypermagnesemia may produce tall, peaked T waves, prolonged PR intervals, and widened QRS complexes that closely resemble severe hyperkalemia on ECG.[20] Moderate-to-severe magnesium toxicity may also mimic acute peripheral neuropathies and neuromuscular junction disorders because of profound loss of deep tendon reflexes and flaccid paralysis.[21] Important diagnostic considerations include botulism, Guillain-Barré syndrome, myasthenia gravis, Lambert-Eaton syndrome, tick paralysis, and spinal cord injury with neurogenic shock.

Calcium channel blocker toxicity, sedative-hypnotic overdose, and opioid poisoning may mimic magnesium toxicity, as they also present with marked lethargy, somnolence, bradycardia, and hypotension.[22] The initial management of these conditions comprises immediate measurement of serum magnesium, potassium, calcium, and phosphorus concentrations while simultaneously securing the airway and stabilizing cardiovascular function.

Prognosis

The prognosis depends on the timeliness of recognition and treatment. Diagnosis before the onset of respiratory depression, followed by aggressive management with intravenous calcium and enhanced magnesium elimination through diuretics or hemodialysis, usually results in complete symptom resolution. Long-term quality of life and life expectancy are unaffected in these cases. Untreated severe magnesium toxicity carries a high mortality risk because of progressive flaccid paralysis, respiratory failure, and terminal diastolic cardiac arrest. Multiple case reports describe complete recovery among preterm infants with extreme hypermagnesemia, with serum magnesium concentrations as high as 22.5 mmol/L, following appropriate treatment regardless of whether the etiology was idiopathic or iatrogenic. A case series of 48 adults with severe hypermagnesemia resulting from Dead Sea water poisoning reported a 19% mortality rate, although concurrent hypercalcemia may have contributed to mortality.[23]

Beyond acute magnesium toxicity, hypermagnesemia is associated with increased mortality across multiple clinical populations. A large retrospective study of 65,974 hospitalized patients found that approximately 32% had elevated serum magnesium concentrations on admission. Serum magnesium concentrations of 2.3 mg/dL or greater independently predicted adverse clinical outcomes and demonstrated a concentration-dependent association with in-hospital mortality.[24]

A recent single-center retrospective observational study found that elevated serum magnesium concentrations greater than 2.2 mg/dL independently predicted both hospital admission and 28-day all-cause mortality among adults older than 70 seen in the emergency department.[25] Additional studies have identified hypermagnesemia as a marker of disease severity in patients with COVID-19 and as an independent predictor of increased in-hospital mortality among individuals with acute myocardial infarction.[26][27] Although acute magnesium toxicity is readily diagnosed and treated, hypermagnesemia also serves as an important prognostic marker of adverse clinical outcomes.

Complications

Long-term complications of magnesium toxicity are uncommon when treatment is initiated promptly. Severe toxicity, particularly in patients with impaired renal function, may produce profound cardiovascular and neuromuscular depression. Reduced cardiac output secondary to high-degree atrioventricular block, combined with respiratory muscle paralysis, can precipitate global tissue ischemia quickly. Even brief periods of cerebral hypoxia may result in irreversible anoxic brain injury.

Treatment of severe hypermagnesemia also carries iatrogenic risks. Rapid intravenous fluid resuscitation or repeated calcium administration may precipitate volume overload or rebound hypercalcemia. Emergent hemodialysis carries procedural risks and the potential for intradialytic hemodynamic instability, requiring careful assessment of the anticipated benefits and risks.